TrialHeart and vessels2013

L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Masanori Abe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.